Reporting and representation of participant race and ethnicity in phase III clinical trials for solid tumors.

ABSTRACT:

Background

Including racial and ethnic minorities in clinical trials is essential for advancing health equity. Despite progress, trials often do not mirror patient population demographics.

Methods

The National Library of Medicine's Clinical Trials database was queried for phase III trials of lung, colorectal, breast, and prostate cancers. A reference population was identified from the Surveillance, Epidemiology, and End Result (SEER) database, covering 48% of the US population.

Results

Among 181 trials, race and ethnicity data were included in 86.7% and 60.2% of trials, respectively, with improving reporting over time. Participants were predominantly White (76.3%), followed by Asian/Pacific Islander (14.1%), Black/African American (4.5%), and American Indian/Alaska Na

SUBMITTER: Wang T 

PROVIDER: S-EPMC11792851 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature